SCHEMBL4881997

SCHEMBL4881997

CC(C)C(C)C1CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5663916 0.89 SHBG (0.41)
SCHEMBL23188102 0.87 TRPA1 (0.31)
SCHEMBL18432072 0.86 SHBG (0.46)
SCHEMBL24599441 0.86
SCHEMBL2756929 0.85
SCHEMBL25044891 0.85
SCHEMBL23467251 0.81
SCHEMBL24449724 0.81
SCHEMBL21256232 0.79 IDO1 (0.33)
SCHEMBL22768474 0.78 SLC6A2 (0.37)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080293701-A1 1-Acylamino-2-Hydroxy-3-Amino- -Arylalkanes as Renin Inhibitors VITAE PHARMACEUTICALS, INC. 2008-11-27 US claimed
EP-1844002-A1 1-ACYLAMINO-2-HYDROXY-3-AMINO-W-ARYLALKANES AS RENIN INHIBITORS Vitae Pharmaceuticals, Inc. (US) 2007-10-17 EP claimed
WO-2006083924-A1 1-ACYLAMINO-2-HYDROXY-3-AMINO-W-ARYLALKANES AS RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. (US) 2006-08-10 WO claimed
US-20230227446-A9 PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) 2023-07-20 US disclosed
US-20220213096-A1 PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS NANJING ZHENGXIANG PHARMACEUTICALS CO LTD (CN) 2022-07-07 US disclosed
US-9611278-B2 Soluble guanylate cyclase activators MERCK SHARP & DOHME CORP. (US) 2017-04-04 US disclosed
US-20080293701-A1 1-Acylamino-2-Hydroxy-3-Amino- -Arylalkanes as Renin Inhibitors VITAE PHARMACEUTICALS, INC. 2008-11-27 US disclosed
EP-1844002-A1 1-ACYLAMINO-2-HYDROXY-3-AMINO-W-ARYLALKANES AS RENIN INHIBITORS Vitae Pharmaceuticals, Inc. (US) 2007-10-17 EP disclosed
WO-2006083924-A1 1-ACYLAMINO-2-HYDROXY-3-AMINO-W-ARYLALKANES AS RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. (US) 2006-08-10 WO disclosed
EP-0925368-B1 METHOD FOR PRODUCING ALCOHOLS FREE OF ENANTIOMERS BASF AG (DE) 2002-01-23 EP disclosed
US-6255087-B1 FOR EXAMPLE, ENANTIOSELECTIVE REDUCTION OF 7-(1-OXOETHYL)-1,2,4-TRIAZOLO(1,5-A)PYRIMIDINE TO 7-(1-HYDROXYETHYL)-1,2,4-TRIAZOLO(1,5-A)PYRIMIDINE WITH MICROOGRANISMS IN THE PRESENCE OF GLUCOSE AS CARBON SOURCE BASF AKTIENGESELLSCHAFT (DE) 2001-07-03 US disclosed
EP-0925368-A1 METHOD FOR PRODUCING ALCOHOLS FREE OF ENANTIOMERS BASF AKTIENGESELLSCHAFT (DE) 1999-06-30 EP disclosed
WO-1998037221-A1 METHOD FOR PRODUCING ALCOHOLS FREE OF ENANTIOMERS BASF AKTIENGESELLSCHAFT (DE) 1998-08-27 WO disclosed
WO-1998001427-A1 PROCESS FOR PREPARING PYRAZOLONE DERIVATIVES BASF AKTIENGESELLSCHAFT (DE) 1998-01-15 WO disclosed